RESEARCH ARTICLE

Toxoplasmosis – Awareness and knowledge among medical doctors in Nigeria

Akinwale Michael Efunshile¹ *, Charles John Elikwu², Pikka Jokelainen³,⁴,⁵ *

¹ Department of Medical Microbiology, Ebonyi State University and Federal Teaching Hospital, Abakaliki, Nigeria, ² Department of Medical Microbiology & Parasitology, Ben Carson School of Medicine, Babcock University/Babcock University Teaching Hospital, Ilisan-Remo, Ogun State, Nigeria, ³ University of Helsinki, Helsinki, Finland, ⁴ Estonian University of Life Sciences, Tartu, Estonia, ⁵ Statens Serum Institut, Copenhagen, Denmark

* akinwale.dr.efunshile@daad-alumni.de (AME); pikka.jokelainen@helsinki.fi (PJ)

Abstract

Toxoplasma gondii is a zoonotic parasite causing high disease burden worldwide. A One Health approach is needed to understand, prevent, and control toxoplasmosis, while knowledge gaps in the One Health aspects have been identified among medical professionals in earlier studies. As a One Health collaboration between veterinary and medical fields, we surveyed the knowledge on toxoplasmosis among medical doctors in Nigeria. The knowledge questions, which the participants answered without consulting literature and colleagues, covered epidemiological One Health aspects as well as clinical interspecialty aspects of T. gondii infections. Altogether 522 medical doctors from four tertiary hospitals completed the questionnaire. The mean number of correct answers in the knowledge questions was 7.5, and 8.4% of the participants selected at least 12 of the 17 correct answers. The proportion of medical doctors scoring such a high score was significantly higher among those who reported having seen a case of clinical toxoplasmosis than in those who did not. While 62% of the medical doctors participating in our study knew that cats can shed T. gondii in their feces, 36% incorrectly suggested that humans could do that too. That T. gondii infection can be meatborne was known by 69%, but that it can be also waterborne only by 28% of the medical doctors participating in our study. Most of the medical doctors, 78%, knew that clinical toxoplasmosis may involve the central nervous system, while only 37% answered that it can involve the eyes. Our results suggested knowledge gaps, which need to be addressed in Continuous Medical Education. The identified gaps included both intersectoral One Health aspects and interspecialty aspects: For prevention and management of toxoplasmosis, knowing the main transmission routes and that the parasite can affect several organs is relevant.

Introduction

Toxoplasmosis is a neglected zoonotic parasitic disease that is associated with poverty and causes a high disease burden [1]. Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii, which infects a wide range of warm-blooded animals worldwide [2]. It can be
transmitted by ingestion of the sporulated oocysts via soil, water, or food contaminated with feces of infected and shedding cats and other felines [3]. Another source of infection is undercooked meat of animals harboring infective tissue cysts [4]. Vertical transmission is a well-known transmission route, and iatrogenic transmission may happen via organ transplant [5, 6, 7].

Nigeria with a population of about 180 million is divided into six geopolitical zones: North-East, North-Central, North-West, South-East, South-West and South-South [8]. There is no control program for toxoplasmosis in any of the zones. The seroprevalence was 78.0% among pregnant women in the South-West zone [9] where epidemiological data suggested contact with feline feces as a major source of infection. Prevalence estimates of 32.6–40.8% were observed among pregnant women in other Nigerian studies [10, 11], and a recent study summarized that the mean prevalence of human *T. gondii* infection in Nigeria was 32.0% [12]. Of the more than 350 species of birds and mammals in which *T. gondii* infections have been documented [13], few have been investigated in Nigeria. Seroprevalence estimates of 32.6% in domestic cats [14] and 15.4% in dogs [15], 13.9% in cattle and 29.1% in pigs [16], and 6.7% in sheep and 4.6% in goats [17] have been reported.

Most *T. gondii* infections in immunocompetent individuals of most host species, including humans, are subclinical. The symptoms in humans may include fever and lymphadenopathy, but the infection can lead to severe clinical manifestations and mortality, especially in the immunocompromised and in children with congenital infection [7, 18]. The diagnosis of *T. gondii* infection and toxoplasmosis is usually serological, and molecular methods are used for direct detection of the parasite [19]. Currently, there is no curative treatment, and immunocompetent patients usually do not need treatment.

Because of the zoonotic nature of *T. gondii*, a One Health approach is needed to understand, prevent, and control toxoplasmosis [20]. However, for example, among medical doctors and nurses who provide prenatal care in Brazil [21], knowledge gaps in One Health aspects were evident: despite most of the participants knew that cats can shed the parasite in their feces, more than half of the participants wrongly suggested that dogs could shed as well. We designed our current study as a One Health collaboration between veterinary and medical fields [22], and surveyed the knowledge on toxoplasmosis among medical doctors in Nigeria to identify possible knowledge gaps and need for Continuous Medical Education (CME).

**Materials and methods**

**Ethical statement**

The study was approved by the Ethics and Research Committee of the Federal Teaching Hospital, Abakaliki. Participation was voluntary and anonymous, and no personal data were collected. By filling in the questionnaire, the participants gave consent to use the answers for research purposes. This was explicitly written in the questionnaire (S1 File). A signed written consent was not collected to ensure anonymity of the participants. The results are reported so that individual participants cannot be identified.

**Study design and setting**

We designed a cross-sectional questionnaire-based study that was carried out in four tertiary hospitals in Nigeria. The hospital selection was a convenience selection. Two hospitals were chosen from the South-East geopolitical zone of Nigeria where previous studies on toxoplasmosis were scanty, and two hospitals were chosen from the South-West zone where previous studies had shown high *T. gondii* seroprevalence [12]. Two of the hospitals were located in Ogun state, one in Ebonyi state, and one in Anambra state.
The sample was a convenience sample. We aimed for a sample size of at least 400 participants, based on sample size calculations using OpenEpi software [23]. With expected 10–15% to be classified having high knowledge score, a minimum of 98–138 participants from each hospital were needed for an estimate of the proportion at hospital level at 90% confidence level, and a minimum of 390–552 participants altogether were needed for an overall estimate at 99.9% confidence level. This was evaluated as sufficient to detect differences of relevant magnitude (calculated using 70% and 90%) between two groups, with a power of 80% and two-sided confidence level of 95%.

Anonymous, self-completed questionnaires were used to collect basic background information of the participants and to survey their knowledge on toxoplasmosis using questions on its epidemiology and clinical features, perception of knowing how and when to treat toxoplasmosis, and history of having seen a case of clinical toxoplasmosis. The participants were all medical doctors. Their specialties were not asked to ensure their anonymity, only the overall length of their experience in the medical field was asked.

The questionnaire was a standardized written questionnaire, i.e. administered to all participants in identical format. It was in English, and distributed as printed on a single A4-paper (S1 File). The participants were instructed to answer based on their current knowledge and opinions, without any external information sources. Author(s) were present to ensure no external information sources were used. The participants answered by circling the answers from the options given, and selecting several answers per question was allowed.

Statistical analyses

The 95% confidence intervals (CI) were calculated and preliminary 2-by-2-table comparisons were done using OpenEpi software [23]. Further analyses were performed using Stata IC 13.1 (2013) software (Stata Corporation, TX, USA). P values <0.05 were considered statistically significant.

The logistic regression analyses included gender (dichotomous: female vs. male), length of professional experience (categorized: <5 years, 5–10 years, or >10 years), reportedly knowing how and when to treat toxoplasmosis (dichotomous: “Yes” vs. “No”; “I am not sure” regarded as no data), reportedly having seen a case of clinical toxoplasmosis (dichotomous: “Yes” vs. “No”; “I am not sure” regarded as no data), and scoring a high knowledge score (dichotomous: selecting at least 12 of the 17 correct answers vs. selecting fewer correct answers). The cross-sectional study design did not allow evaluation of the variables on a timeline, and thus model building was done for predicting scoring a high knowledge score and for predicting having seen a case of clinical toxoplasmosis. Multivariable models were built by including all variables with a liberal P value of <0.2 followed by removal of variables that were not statistically significant and did not act as confounders. The predictive ability of the models was evaluated as area under the receiver operating characteristic (ROC) curve, which is both a numerical and a visual tool.

Results

Altogether 522 medical doctors completed the questionnaire (Table 1, S2 File). Of the participants, 33.1% were female and 65.5% were male. Almost half (48.1%) of the participants had 5–10 years of experience in the medical field, while 27.8% reported shorter and 23.2% longer experience. Some participants did not answer all questions; e.g. gender was unknown for seven participants and length of professional experience for five.

The mean number of correct answers in the knowledge questions was 7.5 (range 0–16), and 44 (8.4%) of the participants scored a high score (Tables 1 and 2). Uncertainty was commonly
expressed by the participants. For example, 177 (33.9%) replied that they were not sure whether they know how and when to treat toxoplasmosis, and 78 (14.9%) replied that they were not sure whether they had seen a case of clinical toxoplasmosis. The “not sure” option was also commonly selected for the knowledge questions (Table 2).

The proportion of participants scoring a high score was significantly higher (2-tailed Mid-P exact \( P < 0.05 \)) among those who had reportedly seen a case of clinical toxoplasmosis than in those who had not. A medical doctor who had seen a case of clinical toxoplasmosis had 2.6 (95% CI 1.3–5.4) times higher odds to score a high knowledge score than a medical doctor who did not report seeing one. This univariable model used the data from 442 medical doctors and had low predictive power (area under ROC curve 0.58).

Overall, 17% of the medical doctors who participated in our study reported they had seen a case of clinical toxoplasmosis (Table 1). The proportion was the same, 17%, in the South-East zone and in the South-West zone. The final multivariable model for predicting having seen a case of clinical toxoplasmosis used the data from 324 medical doctors and had three variables: length of professional experience, scoring high knowledge score, and reportedly knowing how and when to treat toxoplasmosis (Table 3). The predictive power of this model was good (area under ROC curve 0.77, the curve extended reasonably well into the upper left corner of the graph).

**Discussion**

Sub-Saharan Africa faces great health management challenges: it bears 25% of global health burden, while it has only 3% of the global health workforce [24]. In Nigeria, the health workforce is mainly concentrated in the urban tertiary health care services [25], which our study focused on. They are key units in the health care and their role in educating the profession is paramount.

The strengths of our study include the good sample size and multi-hospital study design. Due to limited resources, we were unable to cover all six geopolitical zones, and the results

| Table 1. Proportion of medical doctors scoring a high knowledge score in the questionnaire surveying knowledge on toxoplasmosis in Nigeria, by their background information. |
|------------------------------------------------|
| **N** | **n with high score** | **% with high score** | **95% confidence interval** |
|-------|------------------------|-----------------------|---------------------------|
| Hospital 1 (South-East zone) | 164 | 9 | 5.49 | 2.71–9.83 |
| Hospital 2 (South-East zone) | 177 | 19 | 10.73 | 6.78–15.96 |
| Hospital 3 (South-West zone) | 61 | 9 | 14.75 | 7.44–25.35 |
| Hospital 4 (South-West zone) | 117 | 7 | 5.98 | 2.65–11.47 |
| Female | 173 | 10 | 5.78 | 2.97–10.06 |
| Male | 342 | 34 | 9.94 | 7.10–13.46 |
| Experience <5 years | 144 | 12 | 8.33 | 4.59–13.74 |
| Experience 5–10 years | 252 | 21 | 8.33 | 5.37–12.25 |
| Experience >10 years | 121 | 11 | 9.09 | 4.87–15.25 |
| Reportedly knows how and when to treat toxoplasmosis | 165 | 18 | 10.91 | 6.80–16.38 |
| Reportedly does not know how and when to treat toxoplasmosis | 181 | 16 | 8.84 | 5.32–13.67 |
| Has seen a case of clinical toxoplasmosis | 75 | 13 | 17.33 | 10.00–27.15 |
| Has not seen a case of clinical toxoplasmosis | 367 | 27 | 7.36 | 5.00–10.38 |
| All | 522 | 44 | 8.43 | 6.27–11.05 |

https://doi.org/10.1371/journal.pone.0189709.t001
Table 2. Distribution of answers of medical doctors to the knowledge questions on toxoplasmosis. The seventeen answers that were considered correct are highlighted with bold font.

| Question                                                                 | n selecting this answer | % selecting this answer (N = 522) | 95% confidence interval |
|--------------------------------------------------------------------------|--------------------------|-----------------------------------|-------------------------|
| *Toxoplasma gondii* is a bacterium                                       | 29                       | 5.56                              | 3.82–7.78               |
| *Toxoplasma gondii* is a virus                                           | 15                       | 2.87                              | 1.68–4.59               |
| *Toxoplasma gondii* is a parasite                                       | 419                      | 80.27                             | 76.69–83.51             |
| *Toxoplasma gondii* is a fungi                                          | 27                       | 5.17                              | 3.51–7.34               |
| *Toxoplasma gondii* is an insect                                        | 0                        | 0.00                              | 0.00–0.57               |
| Not sure what *T. gondii* is                                            | 20                       | 3.83                              | 2.42–5.75               |
| *Toxoplasma gondii* can infect humans                                    | 419                      | 80.27                             | 76.69–83.51             |
| *Toxoplasma gondii* can infect pigs                                      | 97                       | 18.58                             | 15.42–22.09             |
| *Toxoplasma gondii* can infect sheep                                     | 69                       | 13.22                             | 10.51–16.33             |
| *Toxoplasma gondii* can infect camels                                    | 28                       | 5.36                              | 3.66–7.56               |
| *Toxoplasma gondii* can infect dogs                                      | 115                      | 22.03                             | 18.63–25.74             |
| *Toxoplasma gondii* can infect cats                                      | 298                      | 57.09                             | 52.81–61.29             |
| *Toxoplasma gondii* can infect fish                                      | 4                        | 0.77                              | 0.24–1.84               |
| *Toxoplasma gondii* can infect chicken                                   | 7                        | 1.34                              | 0.59–2.64               |
| Not sure what *T. gondii* can infect                                     | 21                       | 4.02                              | 2.57–5.98               |
| *Toxoplasma gondii* can be shed in the feces of humans                   | 186                      | 35.63                             | 31.61–39.81             |
| *Toxoplasma gondii* can be shed in the feces of pigs                     | 56                       | 10.73                             | 8.29–13.61              |
| *Toxoplasma gondii* can be shed in the feces of sheep                    | 44                       | 8.43                              | 6.27–11.05              |
| *Toxoplasma gondii* can be shed in the feces of camels                   | 11                       | 2.11                              | 1.11–3.63               |
| *Toxoplasma gondii* can be shed in the feces of dogs                     | 108                      | 20.69                             | 17.38–24.33             |
| *Toxoplasma gondii* can be shed in the feces of cats                     | 324                      | 62.07                             | 57.84–66.16             |
| *Toxoplasma gondii* can be shed in the feces of fish                     | 4                        | 0.77                              | 0.24–1.84               |
| *Toxoplasma gondii* can be shed in the feces of chicken                  | 2                        | 0.38                              | 0.06–1.26               |
| *Toxoplasma gondii* can be shed in the feces of spiders                  | 0                        | 0.00                              | 0.00–0.57               |
| Not sure what can shed *T. gondii* in the feces                          | 65                       | 12.45                             | 9.82–15.50              |
| *Toxoplasma gondii* infection can be meatborne                           | 361                      | 69.16                             | 65.09–73.01             |
| *Toxoplasma gondii* infection cannot be meatborne                        | 46                       | 8.81                              | 6.60–11.48              |
| Not sure whether *T. gondii* infection can be meatborne                  | 105                      | 20.11                             | 16.84–23.72             |
| *Toxoplasma gondii* infection can be waterborne                         | 146                      | 27.97                             | 24.24–31.94             |
| *Toxoplasma gondii* infection cannot be waterborne                      | 178                      | 34.10                             | 30.13–38.25             |
| Not sure whether *T. gondii* infection can be waterborne                | 190                      | 36.40                             | 32.35–40.60             |
| Clinical toxoplasmosis may involve: central nervous system               | 407                      | 77.97                             | 74.26–81.37             |
| Clinical toxoplasmosis may involve: fetus                               | 227                      | 43.49                             | 39.28–47.77             |
| Clinical toxoplasmosis may involve: Red blood cells                      | 37                       | 7.09                              | 5.11–9.54               |
| Clinical toxoplasmosis may involve: Lungs                                | 116                      | 22.22                             | 18.81–25.94             |
| Clinical toxoplasmosis may involve: Eyes                                 | 193                      | 36.97                             | 32.91–41.18             |
| Not sure what clinical toxoplasmosis may involve                        | 48                       | 9.20                              | 6.94–11.91              |

(Continued)
may thus not represent all the zones. Interestingly, there was no obvious difference between the results from the South-East geopolitical zone where previous studies on toxoplasmosis were scanty, and from the South-West zone where previous studies showed high *T. gondii* seroprevalence (Table 1) [12]. The study was planned carefully and the questionnaire was a standardized written questionnaire, administered to all participants in identical format, which increases its reliability. The low-cost study design was successful, and the multi-hospital collaboration as well as the international collaboration between the veterinary and medical fields were exemplary and encouraging. The major limitations of our study arose from the cross-sectional study design, convenience sample, and limited background information of the participants. Moreover, validity of the perception question was not evaluated, and we had no time limit for the question about having seen a case.

We defined high knowledge score as selecting at least 12 of the 17 correct answers (Table 2). This was reached by less than a tenth of the medical doctors participating in our study. What score could be seen as good or adequate was not defined in this study–some of the knowledge questions may be considered trivial, while the baseline knowledge and awareness of the One Health aspects and numerous possible clinical manifestations are important. It should be emphasized that the participants answered without using any external information sources, while consulting literature and colleagues are normal practices in medical profession. The questionnaire perhaps made the participants reflect on their knowledge and select "not sure" fairly easily (Table 2). Uncertainty was also evident in the self-reporting of knowing how and when to treat toxoplasmosis (Table 1). It should be emphasized that the question measured self-reported perception, and it remains unknown whether the 32% answering they knew how and when to treat toxoplasmosis actually did, as well as whether the 35% answering they did not know referred to the wide range of clinical manifestations.

### Table 2. (Continued)

|                                | n selecting this answer | % selecting this answer (N = 522) | 95% confidence interval |
|--------------------------------|-------------------------|-----------------------------------|-------------------------|
| Most *T. gondii* infections are subclinical | 365                     | 69.92                             | 65.88–73.74            |
| Most *T. gondii* infections are not subclinical | 48                      | 9.20                              | 6.94–11.91             |
| Not sure whether most *T. gondii* infections are subclinical | 102                     | 19.54                             | 16.31–23.11            |
| Toxoplasma gondii can cause blindness | 320                     | 61.30                             | 57.07–65.41            |
| Toxoplasma gondii cannot cause blindness | 43                      | 8.24                              | 6.10–10.84             |
| Not sure whether *T. gondii* can cause blindness | 157                     | 30.08                             | 26.26–34.12            |

https://doi.org/10.1371/journal.pone.0189709.t002

### Table 3. Multivariable logistic regression model for predicting having seen a case of clinical toxoplasmosis among medical doctors in Nigeria.

|                                | Odds ratio | 95% confidence interval | P value |
|--------------------------------|------------|-------------------------|---------|
| Experience <5 years            | Reference  |                         |         |
| Experience 5–10 years          | 2.6        | 1.1–6.5                 | 0.036   |
| Experience >10 years           | 3.3        | 1.3–8.8                 | 0.016   |
| Lower knowledge score          | Reference  |                         |         |
| High knowledge score           | 2.9        | 1.2–7.3                 | 0.019   |
| Reportedly not knowing how and when to treat toxoplasmosis | Reference |                         |         |
| Reportedly knowing how and when to treat toxoplasmosis | 6.7        | 3.3–13.7                | 0.000   |

https://doi.org/10.1371/journal.pone.0189709.t003
Some aspects about toxoplasmosis appeared better known, for example, 62% of the medical doctors participating in our study knew that cats can shed *T. gondii* in their feces, 69% knew that *T. gondii* infection can be meatborne, and 78% knew that clinical toxoplasmosis may involve the central nervous system (Table 2). However, several knowledge gaps were identified, as, for example, more than a third of the medical doctors participating in our study wrongly suggested that humans could shed *T. gondii* in their feces, a small proportion knew the parasite can infect chicken, less than a third knew *T. gondii* infection can be waterborne, and only a bit more than a third knew ocular involvement is possible (Table 2). For management of toxoplasmosis and for providing efficient advice regarding preventing it, knowing that the parasite can affect several organs and understanding the main transmission routes are relevant. The knowledge gaps we identified can be addressed in Continuous Medical Education (CME), and interspecialty and intersectoral collaboration could help in widening the discussion to cover the different aspects and One Health thinking.

The topic, *T. gondii* -related knowledge among healthcare professionals, has been of research interest in several countries [21, 26–30], however the studies are not easily comparable due to different approaches and focuses. Comparing our findings with the results of the study among 118 health care workers in Brazil [21] as well as with the results of another similar study among 100 medical doctors in Mexico [26] suggested that the epidemiological aspects of toxoplasmosis were better known in Brazil and Mexico than in Nigeria: for example, 95.8% (95% CI not provided) in Brazil [21] and 89.0% (95% CI not provided) in Mexico [26] knew that *T. gondii* can be shed by cats, whereas a significantly lower proportion of medical doctors in Nigeria, 62.07% (95% CI 57.84–66.16), indicated knowing this by selecting the correct answer (2-tailed Mid- *P* exact *P* <0.001 for both comparisons). The majority of the participants in all three studies indicated knowing that *T. gondii* infection is mostly subclinical: 73.9% (95% CI not provided) in Brazil [21], 59.0% (95% CI not provided) in Mexico [26], and 69.92% (95% CI 65.88–73.74) in our study in Nigeria. These three proportions are not directly comparable due to differently formulated questions.

The logistic regression models suggested association between having seen a case of clinical toxoplasmosis and scoring a high knowledge score, but the data did not allow placing these on a timeline. Moreover, whether this association could be partly explained by specialties of the participating medical doctors could not be evaluated in this study. We can only speculate around the association, in both possible directions, more generally: it is possible that having seen a case encouraged reading and learning about the parasite, as well as that knowing the parasite well helped to keep it on the list of differential diagnoses and thus made it more likely to detect a case. While the incidence of clinical toxoplasmosis will hopefully decline in the future decades, case-based CME could be emphasized.

Conclusions

While many aspects of *T. gondii* were known by the majority of the medical doctors participating in our study, our results suggested knowledge gaps in intersectoral One Health aspects and interspecialty aspects of the zoonotic parasite. These knowledge gaps should be addressed in CME and by intersectoral and interspecialty collaboration. The observed association between having seen a case of clinical toxoplasmosis and scoring a high knowledge score encourages using a case-based approach in CME.

Supporting information

S1 File. The questionnaire to survey knowledge on toxoplasmosis among medical doctors.
S2 File. Dataset.
(XLSX)

Acknowledgments
We are grateful for late C.C. Egwuatu for his contributions to this study. We warmly thank all the participants, and the hospitals for the collaboration.

Author Contributions
Conceptualization: Akinwale Michael Efunshile, Pikka Jokelainen.
Data curation: Akinwale Michael Efunshile, Pikka Jokelainen.
Formal analysis: Pikka Jokelainen.
Investigation: Akinwale Michael Efunshile, Charles John Elikwu.
Methodology: Pikka Jokelainen.
Project administration: Akinwale Michael Efunshile, Pikka Jokelainen.
Resources: Akinwale Michael Efunshile, Pikka Jokelainen.
Supervision: Akinwale Michael Efunshile, Pikka Jokelainen.
Validation: Akinwale Michael Efunshile, Charles John Elikwu, Pikka Jokelainen.
Visualization: Akinwale Michael Efunshile, Pikka Jokelainen.
Writing – original draft: Akinwale Michael Efunshile, Pikka Jokelainen.
Writing – review & editing: Akinwale Michael Efunshile, Charles John Elikwu, Pikka Jokelainen.

References
1. Hotez PJ. Neglected Parasitic Infections and Poverty in the United States. PLoS Negl Trop Dis. 2014; 8 (9): e3012. https://doi.org/10.1371/journal.pntd.0003012 PMID: 25188455
2. Furtado JM, Smith JR, Belfort R Jr, Gattey D, Winthrop KL. Toxoplasmosis: a global threat. J Glob Infect Dis. 2011; 3: 281–284. https://doi.org/10.4103/0974-777X.83536 PMID: 21887062
3. Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the United States, 1999–2004, decline from the prior decade. Am J Trop Med Hyg. 2007 77: 405–410. PMID: 17827351
4. Dubey JP. Toxoplasmosis. J. Am. Vet. Med. Assoc.1994; 205: 1593–1598. PMID: 7730132
5. Robert-Gangneux F, Yera H, D’Herve D, Guiguen C. Congenital toxoplasmosis after a preconceptional or periconceptional maternal infection. Pediatr Infect. Dis. J. 2008; 28: 660–661. https://doi.org/10.1097/INF.0b013e3181985e60 PMID: 19661432
6. Acha PN, Szyfres B. Zoonoses and communicable diseases common to man and animals. Pan American Health Organization. 2001. Available from: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=19187&Itemid=270
7. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004; 363: 1965–1976. https://doi.org/10.1016/S0140-6736(04)16412-X PMID: 15194258
8. Ekong PS, Ducheyne E, Carpenter TE, Owolodun OA, Oladokun AT, Lombin LH, et al. Spatio-temporal epidemiology of highly pathogenic avian influenza (H5N1) outbreaks in Nigeria, 2006–2008. Prev Vet Med. 2012; 103: 170–177. https://doi.org/10.1016/j.prevetmed.2011.10.001 PMID: 22079423
9. Onadeko MO, Joyson DH, Payne RA. The prevalence of Toxoplasma infection among pregnant women in Ibadan, Nigeria. J Trop Med Hyg. 1992; 95: 149–145. PMID: 1560485
10. Deji-Agboola AM, Busari OS, Osinupebi OA, Amoo AOJ. Seroprevalence of Toxoplasma gondii Antibodies among Pregnant Women Attending Antenatal Clinic of Federal Medical Center, Lagos, Nigeria. Int J Biol Med Res. 2011; 2: 1135–1139.

11. Akinbami AA, Adewunmi AA, Rabiu KA, Write KO, Dosunmu AO, Dada MO, et al. Seroprevalence of Toxoplasma Gondii Antibodies amongst Pregnant Women at the Lagos State University Teaching Hospital, Nigeria. Niger Postgrad Med J. 2010; 17: 164–167. PMID: 20539334

12. Ohiolei JA, Isaac C. Toxoplasmosis in Nigeria: the story so far (1950–2016): a review. Folia Parasitol. 2016; 63: pii: 2016.030. https://doi.org/10.14411/fp.2016.030 PMID: 27579591

13. Lindsay DS, Dubey JP. Toxoplasmosis in wild and domestic animals, In Weiss LM, Kim K. Toxoplasma gondii: the model apicomplexan. Perspectives and methods. Academic Press, London, United Kingdom; 2007. pp. 133–152.

14. Kamani J, Mani AU, Kumshe HA, Yidawi JP, Egwu GO. Prevalence of Toxoplasma gondii antibodies in cats in maiduguri, northeastern nigeria. Acta Parasitologica. 2010; 55: 94–95.

15. Aganga AO, Ortese AA. A serologic survey of Toxoplasma gondii in pet dogs in Nigeria. Br Vet J. 1984; 140: 207–209. https://doi.org/10.1016/0007-1935(84)90083-6 PMID: 6722507

16. Onyiche TE, Ademola IO. Seroprevalence of anti-Toxoplasma gondii antibodies in cattle and pigs in Ibadan, Nigeria. J Parasit Dis. 2015; 39: 309–314. https://doi.org/10.1007/s12639-013-0350-1 PMID: 26064025

17. Kamani J, Mani AU, Egwu GO. Seroprevalence of Toxoplasma gondii infection in domestic sheep and goats in Borno state, Nigeria. Trop Anim Health Prod. 2010; 42: 793–787. https://doi.org/10.1007/s11250-009-9488-3 PMID: 19882227

18. Remington JS, Mcleod R, Desmonts G. Toxoplasmosis. In: Remington JSand Klein JO. eds. Infectious disease of the foetus and newborn infant. Philadelph ia: W. B. Saunders Company ; 1995. pp. 140–267.

19. Robert-Gangneux F, Darde ML. Epidemiology of and Diagnostic Strategies for Toxoplasmosis. Clin Microbiol Rev. 2012; 25;2: 264–296. https://doi.org/10.1128/CMR.05013-11 PMID: 22491772

20. Shrivastava SR, Shrivastava PS, Ramasamy J. Neglected zoonotic diseases: It’s now time for action urges WHO. J Res Med Sci. 2015; 20: 1125–1126. https://doi.org/10.4103/1735-1995.172854 PMID: 26941820

21. da Silva LB, de Oliveira RVC, da Silva MP, Bueno WF, Amendoeira MRR, de Souza Neves E. Knowledge of Toxoplasmosis among Doctors and Nurses who provide prenatal care in an endemic region. Infect Dis Obstet Gynecol. 2011; 2011: 750484. https://doi.org/10.1155/2011/750484 PMID: 21747644

22. Kahn LH. Confronting Zoonoses, Linking Human and Veterinary Medicine. Emerg Infect Dis. 2006; 12: 556–561. https://doi.org/10.3201/eid1204.050956 PMID: 16704801

23. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open source epidemiologic statistics for public health. Available from: http://www.openepi.com

24. WHO. Global Health Observatory (GHO), Health Workforce. Available from: www.who.int/gho/health_workforce/en/index.html

25. Global health workforce alliance. Available from: http://www.who.int/workforcealliance/countries/nga/en/

26. Alvarado-Esquível C, Sifuentes-Álvarez A, Estrada-Martínez S, Rojas-Rivera A. Conocimientos y prácticas sobre toxoplasmosis en médicos que atienden a mujeres embarazadas en Durango, México [in Spanish, with English summary] Gac Med Mex. 2011; 147: 311–324.

27. Davis SM, Anderson BL, Schulkin J, Jones K, Vanden Eng J, Jones JL. Survey of obstetrician-gynecologists in the United States about toxoplasmosis: 2012 update. Arch Gynecol Obstet. 2015; 291: 545–555. https://doi.org/10.1007/s00404-014-3450-y PMID: 25205181

28. Kravetz JD, Federman DG. Prevention of toxoplasmosis in pregnancy: knowledge of risk factors. Infect Dis Obstet Gynecol. 2005; 13: 161–165. https://doi.org/10.1080/10647440500068305 PMID: 16126501

29. Ziemba J, Nowakowska-Giab A, Wilczyński J, Maniecka-Bryła I, Nowakowska D. OCENA STANU WIEDZY DOTYCZĄCEJ TOKSOPŁAZMOZY ŚRÓD CIĘŻARNYCH, POŁOŻNYCH, STUDENTÓW MEDYCyny I LEKARZY POŁOŻNIKÓW [in Polish, with English summary]. Med Pr. 2010; 61: 271–276.

30. Lum F, Jones JL, Holland GN, Liesegang TJ. Survey of ophthalmologists about ocular toxoplasmosis. Am J Ophthalmol. 2005; 140: 724–726. https://doi.org/10.1016/j.ajo.2005.04.048 PMID: 16226526